Verified peer comparison

BDX vs ABT

Becton, Dickinson and Company compared with Abbott Laboratories. This page compares both source-verified company profiles and does not introduce an unverified price target.

BDX

Becton, Dickinson and Company

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABT

Abbott Laboratories

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

BDX: Health Care Equipment

ABT: Health Care Equipment

Upside lens

BDX: A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies. New pharmacy automation, microbiology and interventional products can improve mix and customer workflows. A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.

ABT: Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

Risk lens

BDX: Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits. Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs. Provider labor and capital constraints can delay equipment upgrades and pressure pricing.

ABT: Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

Verified sources

BD Reports Second Quarter Fiscal 2026 Financial ResultsBecton, Dickinson and Company · earningsVerified